Stockscreener 앱 받기
39.56
0.35%
-0.14
시간 외 거래:
40.09
0.53
+1.34%
전일 마감가:
$39.70
열려 있는:
$40.06
하루 거래량:
742.32K
Relative Volume:
0.79
시가총액:
$3.16B
수익:
$541.74M
순이익/손실:
$88.01M
주가수익비율:
36.42
EPS:
1.0862
순현금흐름:
$155.34M
1주 성능:
+19.99%
1개월 성능:
+27.24%
6개월 성능:
-6.48%
1년 성능:
+28.61%
1일 변동 폭
$39.17
$40.97
1주일 범위
$35.54
$42.10
52주 변동 폭
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
39.56 | 3.17B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Underweight |
| 2025-10-20 | 개시 | Canaccord Genuity | Hold |
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Number of shareholders of Veracyte, Inc. – MUN:12V - TradingView
Veracyte price target raised to $42 from $40 at Canaccord - TipRanks
Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives - Sahm
VCYT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
The Nasdaq Biotechnology Index closed up more than 2.1%. Among its constituents, Pyxis Oncology rose 25.68%, Veracyte gained 25.08%, MannKind (MNKD) increased 24.83%, Replimune was up 19.16%, and Novavax (NVAX) rose 15.56%. - Bitget
Veracyte (VCYT) Jumps As Strong Q1 Fuels Bullish Guidance - timothysykes.com
Ann McGuire sells 6,658 shares under 10b5-1 plan (VCYT) - Stock Titan
Veracyte Surges 21.1% Amid Sector-Wide Rally - AlphaStreet
UBS Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Veracyte, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Key Risks, and Results Overview - Minichart
VCYT Stock Jumps As Raised Guidance Fuels Bullish Momentum - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
FMR LLC (NASDAQ: VCYT) discloses 9.7% holding — 7.7M shares - Stock Titan
UBS Adjusts Price Target on Veracyte to $52 From $48, Maintains Buy Rating - marketscreener.com
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $42 to $48 - Moomoo
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript - Insider Monkey
Veracyte, Inc. 1Q 2026: Revenue $139.07M, EPS $0.35— 10-Q Summary - TradingView
Veracyte (NASDAQ: VCYT) Q1 profit surges as revenue climbs 21% - Stock Titan
Veracyte Q1 2026 slides: EPS beats by 57%, guidance raised - Investing.com Australia
Veracyte Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Revenue Guidance; Shares Up Pre-Bell - marketscreener.com
Veracyte: Raising FY26 Testing Rev Guidance to $570M to $580M >VCYT - Moomoo
Veracyte Announces First Quarter 2026 Financial Results - BioSpace
Veracyte Q1 Earnings Call Highlights - Yahoo Finance
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Earnings call transcript: Veracyte Q1 2026 beats EPS forecast by 57% - Investing.com UK
Veracyte Inc Earnings Call Signals Profitable Growth - TipRanks
Veracyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge - ChartMill
Earnings call transcript: Veracyte Q1 2026 beats EPS forecast by 57% By Investing.com - Investing.com Australia
Veracyte : VCYT Q1 2026 Earnings Presentation Final - marketscreener.com
Veracyte (VCYT) Q1 2026 Earnings Transcript - AOL.com
Full Transcript: Veracyte Q1 2026 Earnings Call - Benzinga
Veracyte: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (VCYT) Veracyte, Inc. Reports Q1 Revenue $139.1M, vs. FactSet Est of $130.4M - marketscreener.com
Earnings Flash (VCYT) Veracyte, Inc. Posts Q1 Adjusted EPS $0.52 per Share - marketscreener.com
Q1 2026 Veracyte Inc Earnings Call Transcript - GuruFocus
Cancer test maker Veracyte posts $28.7M profit, raises outlook - Stock Titan
Veracyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Veracyte (NASDAQ: VCYT) boosts Q1 profit and raises 2026 outlook - Stock Titan
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
0.56%
자본화:
|
볼륨(24시간):